Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Published version of a preprint
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
H-Ras, K-Ras, and N-Ras regulate cellular growth and survival and are often activated by somatic mutation in human tumors. Although oncogenic lesions occur in a single Ras isoform within individual tumors, it is unclear whether the remaining wild-type isoforms play supporting roles in tumor growth. Here, we show that oncogenic and wild-type Ras isoforms play independent and nonredundant roles within the cell. Oncogenic Ras regulates basal effector pathway signaling, whereas wild-type Ras mediates signaling downstream of activated receptor tyrosine kinases (RTK). We show that both are necessary for exponential growth of Ras-mutant cell lines. Furthermore, we show that oncogenic Ras desensitizes signaling from EGF receptor (EGFR). Depletion of oncogenic Ras with siRNA oligonucleotides relieves this negative feedback, leading to the hyperactivation of EGFR and wild-type Ras signaling. Consistent with this model, combining oncogenic Ras depletion with EGFR inhibition potently increases cell death. Significance: The results of this study highlight a novel role for wild-type Ras signaling in cancer cells harboring oncogenic RAS mutations. Furthermore, these findings reveal that therapeutically targeting oncogenic Ras signaling alone may be ineffective owing to feedback activation of RTKs, and suggest that blocking upstream RTKs in combination with downstream effector pathways may be beneficial in the treatment of Ras-mutant tumors. Cancer Discov; 3(1); 112–23. ©2012 AACR. See related commentary by Hayes and Der, p. 24 This article is highlighted in the In This Issue feature, p. 1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“this mechanism of action is unlikely to be effective against the second mechanism of adaptive feedback (RTK-driven activation of wild type RAS) (33).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [33]
In the citing paper
“Therefore, genetic depletion of oncogenic RAS with siRNA oligonucleotides relieves this negative feedback, leading to hyperactivation of EGFR and wild-type RAS signaling [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“Previous studies have shown that oncogenic RAS regulates the basal effector pathway, whereas wild-type RAS mediates signaling downstream of the activated receptor tyrosine kinases [41].”
From Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer (2023) · cites this paper as [41]
In the citing paper
“WT RAS alleles have been shown to be critical in maintaining the growth and signaling of RAS-mutant cell lines, especially from extracellular signals through RTKs and flux through the MAPK pathway (Cheng et al., 2021; Young et al., 2013; Zhou et al., 2016).”
From KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy (2022) · cites this paper as Young et al., 2013
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 2×
“Oncogenic RAS alleles differ from their wild-type counterpart by a single missense point mutation that results in an amino acid substitution typically at position 12, 13, or 61 (6, 7).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 2×
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Oncogenic mutation in any one of the three RAS genes is thought to be sufficient to constitutively activate downstream signaling and confer independence from upstream growth cues (8).”
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 9×
“The aberrant hyperactivation of Ras plays a causal role in human cancer, and an estimated 30% of human tumors harbor oncogenic somatic mutations in HRAS , KRAS , or NRAS ( 5, 6 ).”
InfluentialKinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465 · cited 1×
“Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18-20).”
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
“…the remaining wild-type (WT) RAS proteins present in RAS-mutant cancers in contributing to cancer growth (Grabocka et al., 2014; Lim et al., 2008; Young et al., 2013), although other studies suggest that WT RAS can act as a tumor suppressor (Bremner and Balmain, 1990; Qiu et al., 2011; To et…”
BackgroundResultStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
“It is also clear that knocking down activated Ras can lead to hyperactivation of upstream pathways, such as EGFR signaling (Young et al., 2013).”
BackgroundSelf-citationSelective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
“KRAS Biochemical Modification Assay GDP-loaded, hexahistidine-tagged, truncated (1-169) KRAS proteins (G12C, WT, G13D, as indicated) at 2 μmol/L final concentration were incubated with the test compounds at the doses and time points indicated in a buffer containing 20 mmol/L HEPES pH 7.”
BackgroundMethodInfluentialVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Perera, T. P. S., Jovcheva, E., Mevellec, L., Vialard, J., De Lange, D., Verhulst, T., Paulussen, C., Van De Ven, K., King, P., Freyne, E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0589 · Cited by 334
McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320
Self-citationAn orthosteric inhibitor of the Ras-Sos interaction
Patgiri, A., Yadav, K. K., Arora, P. S., & Bar-Sagi, D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.612 · Cited by 295
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
“Proposed molecularmechanisms includecompetition for propermembrane localization, shared regulators, downstreammediators, or activation of parallel signaling pathways (Young et al., 2013).”
BackgroundTP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma
Somerville, T. D. D., Xu, Y., Miyabayashi, K., Tiriac, H., Cleary, C. R., Maia-Silva, D., Milazzo, J. P., Tuveson, D. A., & Vakoc, C. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.051 · Cited by 225
“(C and D) ChIP-seq profiles of TP63, FLAG-tagged ∆Np63, and H3K27ac at the ∆Np63 target genes HRAS (C) and CXCL8 (D) following TP63 knockout in BxPC3-Cas9 cells or expression of ∆Np63 in SUIT2 cells.”
BackgroundInfluentialSmall-molecule modulation of Ras signaling
Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N., & Waldmann, H. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1560 · Cited by 214
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199
“Signaling from these WT isoforms of Ras can support the growth of cancer cells harboring oncogenic Ras mutations (17), and inhibiting nucleotide exchange is a valid approach to abrogate signaling arising from both mutant and WT Ras (11).”
BackgroundPeeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
“Activating mutations in RAS can result in persistent signaling in the 5 absence of ligand binding to the EGFR, and resistance to therapy with the anti-EGFR 6 monoclonal antibodies panitumumab and cetuximab (3,4).”
BackgroundKRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110993 · Cited by 177
“WT RAS alleles have been shown to be critical in maintaining the growth and signaling of RAS-mutant cell lines, especially from extracellular signals through RTKs and flux through the MAPK pathway (Cheng et al., 2021; Young et al., 2013; Zhou et al., 2016).”
BackgroundMechanism for activation of mutated epidermal growth factor receptors in lung cancer
Red Brewer, M., Yun, C.-H., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 148
“Interestingly, others have found that oncogenicK-Ras can activate theWTRas isoforms H- or N-Ras via Sos, and that the K-Ras–dependent activation of WT Ras isoforms contributes to cellular signaling and tumorigenesis (37, 38).”
BackgroundDifferential effector engagement by oncogenic KRAS
Yuan, T. L., Amzallag, A., Bagni, R., Yi, M., Afghani, S., Burgan, W., Fer, N., Strathern, L. A., Powell, K., Smith, B., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.051 · Cited by 150
“The relative sensitivity of the KRAS subtype to erlotinib and the wildtype RAS isoforms, HRAS and NRAS, supports the notion that KRAS-type lines require receptor tyrosine kinases (RTKs) to recruit GEFs for nucleotide exchange of RAS (Lito et al., 2016; Patricelli et al., 2016; Young et al., 2013).”
BackgroundSelf-citationOlea-Flores, M., Zuñiga-Eulogio, M. D., Mendoza-Catalán, M. A., Rodríguez-Ruiz, H. A., Castañeda-Saucedo, E., Ortuño-Pineda, C., Padilla-Benavides, T., & Navarro-Tito, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122885 · Cited by 146
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
Yohe, M. E., Gryder, B. E., Shern, J. F., Song, Y. K., Chou, H.-C., Sindiri, S., Mendoza, A., Patidar, R., Zhang, X., Guha, R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4470 · Cited by 145
Grabocka, E., Pylayeva-Gupta, Y., Jones, M. J. K., Lubkov, V., Yemanaberhan, E., Taylor, L., Jeng, H. H., & Bar-Sagi, D. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.005 · Cited by 145
“The capacity of WT-Ras to negatively regulate effector pathway signaling in mutant Ras cancer cells is consistent with earlier reports showing that the levels of WT-Ras proteins in mutant Ras cancer cell lines are inversely correlated to the activation status of Raseffector molecules (Young et al., 2012; Zhang et al.,…”
InfluentialCharacteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Moran, T., Camidge, D. R., Vnencak-Jones, C. L., Berry, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 142
“mediates signaling downstream of activated receptor tyrosine kinases (39).”
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 113
“However, the response to these therapies differs across KRAS mutant lung cancer cell lines and tumors and might be limited by other factors such as co-occurrence of inactivating mutations in tumor suppressor genes (TP53, STK11, or PTEN),(39,40) or activation of compensatory pathways that will allow cancer cells to con…”
Long non-coding RNA HOTAIR: A novel oncogene (Review)
Yu, X., & Li, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4161 · Cited by 148
“Known oncogene, including Ras, BRAF, β -catenin, and Myc, are predominantly protein-coding genes, the functions of which are mediated by their gene products-proteins (3-6).”
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Hutton, J. E., Wang, X., Zimmerman, L. J., Slebos, R. J. C., Trenary, I. A., Young, J. D., Li, M., & Liebler, D. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058925 · Cited by 131
“signaling through the epidermal growth factor pathway (61).”
BackgroundThe role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
“A cell proliferation defect was seen in the NRAS mutant rhabdomyosarcoma cell line RD (NRASQ61H) upon knockdown of wild type HRAS and/or KRAS [70].”
BackgroundOncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C.-J., & Jang, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122
“Differential behavior of isoforms of wild-type versus their respective mutants In an apparent twist, studies of mouse model carcinogenesis as well as patient tumors seemed to indicate that wild-type Ras can act as tumor suppressor of its mutant form, particularly in KRAS cancers as compared withNRAS (1, 139, 140).”
BackgroundOpposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover
Hong, X., Nguyen, H. T., Chen, Q., Zhang, R., Hagman, Z., Voorhoeve, P. M., & Cohen, S. M. (2014) · The EMBO Journal · doi:10.15252/embj.201489385 · Cited by 121
“High TAZ expression indicates a poor prognosis in colorectal cancer (Yuen et al , 2013).”
Wan, T., Chen, Y., Pan, Q., Xu, X., Kang, Y., Gao, X., Huang, F., Wu, C., & Ping, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.015 · Cited by 118
Ntai, I., Fornelli, L., DeHart, C. J., Hutton, J. E., Doubleday, P. F., LeDuc, R. D., van Nispen, A. J., Fellers, R. T., Whiteley, G., Boja, E. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716122115 · Cited by 108
“Moreover, comparison of cell lines harboring different, allele-specific KRAS mutations has provided an additional level of complexity regarding KRAS-dependent effector signaling (18, 19).”
BackgroundHLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function
Baker, R., Lewis, S. M., Sasaki, A. T., Wilkerson, E. M., Locasale, J. W., Cantley, L. C., Kuhlman, B., Dohlman, H. G., & Campbell, S. L. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2430 · Cited by 101
SOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
“cognition of the critical functional role played by non-mutated, WT RAS proteins in the context of mutant RAS cancers [39,41] has also paved the way for additional, new therapeutic strategies focused on either targeting various downstream effectors of RAS signaling [271] or dis-”
BackgroundFeng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“Therefore, genetic depletion of oncogenic RAS with siRNA oligonucleotides relieves this negative feedback, leading to hyperactivation of EGFR and wildtype RAS signaling [41].”
BackgroundJohanning, G. L., Malouf, G. G., Zheng, X., Esteva, F. J., Weinstein, J. N., Wang‐Johanning, F., & Su, X. (2017) · Scientific Reports · doi:10.1038/srep41960 · Cited by 164
Dynamic regulation of RAS and RAS signaling
Kölch, W., Berta, D., & Rosta, E. (2023) · Biochemical Journal · doi:10.1042/bcj20220234 · Cited by 104
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
“Another study found activation of WT HRAS and NRAS by feedback relief through multiple RTKs as an alternative mechanism for the adaptive resistance to KRAS inhibitors in colorectal cancer cells,(488) which is consistent with the previous findings that the two remaining WT RAS isoforms (NRAS and HRAS) also play crucial…”
Resultp38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Wang, F., Qi, X.-M., Wertz, R., Mortensen, M., Hagen, C. E., Evans, J., Sheinin, Y. M., James, M. A., Liu, P., Tsai, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3281 · Cited by 91
Blaj, C., Schmidt, E. M., Lamprecht, S., Hermeking, H., Jung, A., Kirchner, T., & Horst, D. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2821 · Cited by 90
Rare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Untch, B. R., Anjos, V. D., García-Rendueles, M. E. R., Knauf, J. A., Krishnamoorthy, G. P., Saqcena, M., Bhanot, U. K., Socci, N. D., Ho, A. L., Ghossein, R. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1925 · Cited by 85
“Consistent with results using genetic targeting of oncogenic RAS, treatment with tipifarnib resulted in GTP loading of wild-type RAS, which reactivated downstream signaling (22).”
BackgroundResultDirect Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 84
The Role of Macromolecular Damage in Aging and Age-related Disease
Richardson, A. G., & Schadt, E. E. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu056 · Cited by 72
“For example, one recent report on Ras signaling in cancer demonstrated that mutated forms of Ras that were oncogenic led to a different functional role of the protein compared to the wild-type version of this protein (17).”
BackgroundSite-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
Antic, I., Biancucci, M., Zhu, Y., Gius, D. R., & Satchell, K. J. F. (2015) · Nature Communications · doi:10.1038/ncomms8396 · Cited by 75
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
“There is a clear appreciation that features beyond the scope of our model, such as positive and negative feedback (19, 22, 26, 27, 29), play important contributions to Ras signaling.”
BackgroundRocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 79
Zheng, Z.-Y., Tian, L., Bu, W., Fan, C., Gao, X., Wang, H., Liao, Y.-H., Li, Y., Lewis, M. T., Edwards, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.044 · Cited by 64
“Alternatively, blockage in proliferation caused by oncogenic Ras-induced stresses, such as DNA damage (Grabocka et al., 2014) and MAP kinase pathway desensitization (Young et al., 2013), can be overcome by wild-type Ras present in the same cell.”
BackgroundK-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
“PI3K-Erk crosstalk [69], impaired upstream signals or regulatory feedback loop activation [70] can greatly affect phosphorylation of Erk; thus, it is always necessary to perform other validation experiments for mechanistic conclusions.”
The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells
Fey, D., Matallanas, D., Rauch, J., Rukhlenko, O. S., & Kholodenko, B. N. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.011 · Cited by 61
“There is evidence for crosstalk between the mutant RAS isoform nd the other wildtype RAS isoforms [44].”
BackgroundImplications of KRAS mutations in acquired resistance to treatment in NSCLC
Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 68
“These pathways include the downstream effector protein kinase Cι (PKCι) involved in tumor-initiating cell phenotype through the PKCι/ELF3/ NOTCH3 axis [21]; the EphA2 a receptor tyrosine kinase (RTK) that negatively regulates the KRAS/MEK/ERK pathway after the binding of its ligand ephrin A1 [22]; or the CUB domain–co…”
BackgroundShang, D., Sun, D., Shi, C., Xu, J. L., Shen, M., Hu, X., Liu, H., & Tu, Z. (2020) · Aging Cell · doi:10.1111/acel.13145 · Cited by 65
Jacob, L. S., Vanharanta, S., Obenauf, A. C., Pirun, M., Viale, A. J., Socci, N. D., & Massagué, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0562 · Cited by 61
“Indeed wild-type KRAS has already been shown to inhibit oncogenic RAS signaling (22) as well as suppress cancer growth (23-25).”
BackgroundThe clinical relevance of KRAS gene mutation in non-small-cell lung cancer
Tímár, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 59
Sheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
“In the first model, RTK-dependent activation of wild-type RAS supplements the basal oncogenic signaling from mutant RAS to fully activate downstream effector pathways and promote proliferation in RAS mutant tumor cell lines (11, 14, 15).”
BackgroundTipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer
Hanna, G. J., Guenette, J. P., Chau, N. G., Sayehli, C. M., Wilhelm, C., Metcalf, R. L., Wong, D. J. L., Brose, M. S., Razaq, M., Pérez-Ruiz, E., et al. (2020) · Cancer · doi:10.1002/cncr.33036 · Cited by 63
Sharma, S. B., Lin, C., Farrugia, M. K., McLaughlin, S. L., Ellis, E. J., Brundage, K. M., Salkeni, M. A., & Ruppert, J. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00480-14 · Cited by 63
Vivekanandhan, S., & Mukhopadhyay, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.014 · Cited by 56
“Studies have shown that downregulation of KRAS has led to aberrant activation of EGFR signaling [42].”
BackgroundISOWN: accurate somatic mutation identification in the absence of normal tissue controls
Kalatskaya, I., Trinh, Q. M., Spears, M., McPherson, J. D., Bartlett, J. M. S., & Stein, L. D. (2017) · Genome Medicine · doi:10.1186/s13073-017-0446-9 · Cited by 55
Chen, X., Makarewicz, J. M., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2014) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 46
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
Shankar, S., Tien, J. C.-Y., Siebenaler, R. F., Chugh, S., Dommeti, V. L., Zelenka-Wang, S., Waninger, J. J., Juckette, K. M., Xu, A., Wang, X.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16309-2 · Cited by 51
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01622 · Cited by 45
A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation
Bentley, C., Jurinka, S. S., Kljavin, N. M., Vartanian, S., Ramani, S. R., Gonzalez, L. C., Yu, K., Modrusan, Z., Du, P., Bourgon, R., et al. (2013) · Biochemical Journal · doi:10.1042/bj20121578 · Cited by 44
Yeddula, N., Xia, Y., Ke, E., Beumer, J., & Verma, I. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520110112 · Cited by 43
“EphA2 has been suggested to be one such negative feedback regulator inhibiting KRAS downstream signaling pathways (30, 55).”
BackgroundLin, S. H., Zhang, J., Giri, U. P., STEPHAN, C. C., Sobieski, M. M., Zhong, L., Mason, K. A., Molkentine, J. M., Thames, H. D., Yoo, S. S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000199 · Cited by 47
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“Mechanistically, knockdown of either the mutated RAS isoform or WT RAS differentially altered basal versus RTK-stimulated effector pathway activation [50].”
BackgroundInfluentialA MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Ischenko, I., Petrenko, O., & Hayman, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4538 · Cited by 43
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
Kampen, K. R., ter Elst, A., Mahmud, H., Scherpen, F. J. G., Diks, S. H., Peppelenbosch, M. P., de Haas, V., Guryev, V., & de Bont, E. S. J. M. (2013) · Leukemia · doi:10.1038/leu.2013.342 · Cited by 45
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 44
“Moreover, it has been previously reported that depletion of mutant RAS in heterozygous RAS cells can lead to overactivation of EGFR/RAS signaling from the remaining wild-type RAS (45).”
BackgroundYu, C.-C., Qiu, W., Juang, C. S., Mansukhani, M. M., Halmos, B., & Su, G. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.10.013 · Cited by 41
“Other studies revealed that the disruption of WT RAS isoforms not cognate to the mutant RAS would compromise MAP/ERK signaling, suggesting WT RAS isoforms serve as tumor promoters in this scenario [93; 94; 95].”
BackgroundChemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.
Kaboli, P. J., İmani, S., Jomhori, M., & Ling, K. (2021) · American Journal of Cancer Research · Cited by 73
EGFR phosphorylates FAM129B to promote Ras activation
Ji, H., Lee, J.-H., Wang, Y., Pang, Y., Zhang, T., Xia, Y., Zhong, L., Lyu, J., & Lu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517112113 · Cited by 38
“Discussion Ras activation has been detected in many types of human cancers, and its activity can be regulated by its association with GTP or GDP, facilitated by GEF or GAP proteins, respectively (6).”
BackgroundLiao, T.-J., Jang, H., Nussinov, R., & Fushman, D. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10710 · Cited by 36
Baranyi, M., Molnár, E., Hegedüs, L., Gábriel, Z., Petenyi, F. G., Bordás, F., Lener, V., Ranđelović, I., Cserepes, M., Tóvári, J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02586-x · Cited by 43
“Brie fl y, fi lters were set for human genes and lipidation for post-transcriptional modi fi cations and then screened for S-farnesyl cysteine-modi fi ed entries.”
BackgroundCooperation between Noncanonical Ras Network Mutations
Stites, E. C., Trampont, P. C., Haney, L. B., Walk, S. F., & Ravichandran, K. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.035 · Cited by 34
“The different roles of wild-type and oncogenic mutant Ras in cancer have since become an important topic in cancer biology (Grabocka et al., 2014; Jeng et al., 2012; Lim et al., 2008; Young et al., 2013).”
BackgroundReal-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Zhao, Q., Fujimiya, R., Kubo, S., Marshall, C. B., Ikura, M., Shimada, I., & Nishida, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108074 · Cited by 39
Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 42
Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.016 · Cited by 36
“Anchored, prenylatedHVRmediates the assembly of activeRasmolecules into nanoclusters (5,6), promoting signaling through the mitogen-activated protein kinase (MAPK, Raf/MEK/ERK) pathway and leading to cell proliferation (7,8).”
BackgroundPanitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
Hocking, C. M., & Price, T. J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13498660 · Cited by 36
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Ha, D. P., Huang, B., Wang, H., Rangel, D. F., Krieken, R. V., Liu, Z., Samanta, S., Neamati, N., & Lee, A. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100837 · Cited by 35
Bousquet, M. S., Ma, J., Ratnayake, R., Havre, P. A., Yao, J. G., Dang, N. H., Paul, V. J., Carney, T. J., Dang, L. H., & Luesch, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00860 · Cited by 34
Sabe, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01130-3 · Cited by 30
Signaling pathways that control mRNA turnover
Thapar, R., & Denmon, A. P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.03.026 · Cited by 38
Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31
Yang, L., Bhattacharya, A., Li, Y., Sexton, S., Ling, X., Li, F., & Zhang, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02389-z · Cited by 32
“Our results also indicate that PEPDG278D accomplishes this feat by abolishing both canonical function (tyrosine kinase) and non-canonical function (scaffolding – heterodimerization with other RTKs) of EGFR and HER2 as well as abolishing HER2 regulation of HRAS and NRAS.”
BackgroundInfluentialNi, D., Song, K., Zhang, J., & Lu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112249 · Cited by 29
Romano, D., Maccario, H., Doherty, C., Quinn, N. P., Kölch, W., & Matallanas, D. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01414-12 · Cited by 31
“downstream signals to facilitate mt Ras transformation (41, 42).”
BackgroundInhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“Active Raf phosphorylates MEK1/2 (MAPK kinase 1/2) (De Luca et al., 2012; Young et al., 2013), with signaling propagating down the mitogen-activated protein kinase (MAPK) pathway to activate extracellular signal-regulated kinase (ERK) and transcription factors, such as Elk-1 (Gao et al.”
BackgroundHan, Y., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02040-9 · Cited by 28
“The expression of WT RAS has been shown to be essential for non-cognate oncogenic RAS-mediated MAPK signaling and cell proliferation [33, 34].”
BackgroundLieu, C. H., Hidalgo, M. M., Berlin, J. D., Ko, A. H., Cervantes, A. M. R., LoRusso, P. M., Gerber, D. E., Eder, J. P., Eckhardt, S. G., Kapp, A. V., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0175 · Cited by 29
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 30
Keats, M. A., Han, J. J. W., Lee, Y., Lee, C.-S., & Luo, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0592 · Cited by 27
Discovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
Ji, X. L., Li, H., Wu, G., Zhang, Q., He, X., Wu, Y., Zong, B., Xu, X., Liang, C., Wang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00428 · Cited by 32
Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time
van Hattum, H., & Waldmann, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.001 · Cited by 29
Metadata
- Authors
- Young, A., Lou, D., & McCormick, F.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Cancer Discovery
- Published
- 2013-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 112-123
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1980323101
- Semantic Scholar
- 0fc5d9d29e0913d74b3ea62adbe40a92015d90a3
- Cited by
- 211
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 18 · 2022: 13 · 2021: 14 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 18 · 2016: 14 · 2015: 24 · 2014: 23 · 2013: 15
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS wild-type, Ras isoforms, MAPK signaling, receptor tyrosine kinase, EGFR, negative feedback signaling, combination therapy, EGFR inhibition, tumor cell proliferation
- MeSH terms
- Erlotinib Hydrochloride, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Quinazolines, Genes, ras, Apoptosis, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.